Haemophilia patients led a deputation to the medical superintendent of the Burdwan Medical College and Hospital today as they ...

The two-part Phase 1/2 trial — dubbed BeCoMe-9 (NCT06611436) — was designed to assess the safety and clinical activity of a ...

A medical center in Indianapolis appears to have perfected a new type of treatment for people with hemophilia.

Man becomes first in Indiana to undergo gene therapy for hemophilia B. The procedure aims to address the root cause of the ...

Novo Nordisk has filed its long-acting factor IX, nonacog beta pegol in the US for haemophilia B. Nonacog beta pegol is a glycopegylated recombinant factor IX with a longer half-life, developed ...

But from the day he was born, Elliott was unable to make enough clotting factor IX (nine). Without this crucial clotting component, bleeds are bigger and longer. Bleeds also happen spontaneously ...

Elliott Mason was born unable to make enough of clotting factor IX, a crucial protein which helps to stop us bleeding A "transformational" therapy has effectively cured people with the bleeding ...

while people with haemophilia B do not have enough Factor IX. In the 1970s, a new treatment using donated human blood plasma was developed to replace these clotting agents. But whole batches were ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...